SCHEMBL1455211

SCHEMBL1455211

Cc1ccc2c(Nc3cc(C(=O)Nc4cccc(Br)c4)ccc3Sc3cccc(O)c3)ncnc2n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.50
AKT2 P31751 1/20 0.50
EGFR P00533 11/20 0.42
AURKB Q96GD4 1/20 0.39
INSR P06213 1/20 0.39
LCK P06239 1/20 0.39
LYN P07948 1/20 0.39
SRC P12931 1/20 0.39
KDR P35968 1/20 0.39
POLB P06746 2/20 0.39
NPC1 O15118 2/20 0.39
MAPK1 P28482 2/20 0.39
RAB9A P51151 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
KMT2A Q03164 1/20 0.39
RELA Q04206 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1454277 0.93 PIM1 (0.51) PIM1AKT2AURKBKDRPOLB
SCHEMBL1454641 0.93 PIM1 (0.58) PIM1AKT2EGFRAURKBINSR
SCHEMBL1454719 0.92 PIM1 (0.51) PIM1AKT2EGFRAURKBKDR
SCHEMBL1455267 0.90 EGFR (0.40) PIM1AKT2EGFRAURKBERBB2
SCHEMBL1455867 0.89 PIM1 (0.50) PIM1AKT2EGFRAURKBINSR
SCHEMBL1455530 0.88 EGFR (0.52) EGFRAURKBKDRNPC1MAPK1
SCHEMBL1455346 0.85 PIM1 (0.48) PIM1AKT2EGFRAURKBSRC
SCHEMBL1455262 0.84 PIM1 (0.58) PIM1AKT2AURKBKDR
SCHEMBL1455706 0.84 EGFR (0.45) EGFRAURKBERBB2ERBB4ABCG2
SCHEMBL1454213 0.84 PIM1 (0.60) PIM1AKT2EGFRAURKBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885EGFR 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.